Gene therapy AB-1005: how safe is it years later?

NCT ID NCT07081841

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: AskBio Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AB-1005 (gene therapy)

What this could lead to

If successful, this study could show that AB-1005 is safe and has lasting benefits for people with Parkinson's disease or multiple system atrophy.

What could go wrong

This is an observational follow-up, not a new treatment test. It may not prove effectiveness, and results depend on prior study participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy multiple system atrophy, parkinsonian type Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • University of California San Francisco

    San Francisco, California, 94143, United States